QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)

Pliant Therapeutics (PLRX) Price Target & Analyst Ratings

$22.14
+0.61 (+2.83%)
(As of 05/18/2023 ET)
Compare
Today's Range
$21.00
$22.95
50-Day Range
$21.53
$30.56
52-Week Range
$4.68
$36.64
Volume
1.50 million shs
Average Volume
864,757 shs
Market Capitalization
$1.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.82

Pliant Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 11 Analyst Ratings

Consensus Analyst Price Target

$47.83
116.05% Upside
High Prediction$63.00
Average Prediction$47.83
Low Prediction$33.00
TypeCurrent
5/18/22 to 5/18/23
1 Month Ago
4/18/22 to 4/18/23
3 Months Ago
2/17/22 to 2/17/23
1 Year Ago
5/18/21 to 5/18/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
9 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$47.83$46.55$47.11$38.00
Predicted Upside116.05% Upside83.89% Upside103.48% Upside246.40% Upside
Get Pliant Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.


PLRX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PLRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pliant Therapeutics Stock vs. The Competition

TypePliant TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside116.05% Upside1,414.32% Upside164.04% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/18/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$48.00+122.94%
5/15/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Stavropoulos
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
5/10/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$55.00 ➝ $50.00+112.95%
5/10/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$44.00 ➝ $51.00+126.57%
4/20/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$45.00+49.15%
4/12/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$44.00+73.23%
3/13/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$55.00 ➝ $50.00+78.70%
3/10/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$51.00 ➝ $47.00+64.85%
3/10/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$60.00 ➝ $58.00+103.01%
1/24/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$33.00 ➝ $45.00+48.61%
12/13/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$33.00+73.23%
7/11/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$27.00 ➝ $40.00+111.42%
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












PLRX Price Target - Frequently Asked Questions

What is Pliant Therapeutics's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for Pliant Therapeutics stock is Buy based on the current 11 buy ratings for PLRX. The average twelve-month price prediction for Pliant Therapeutics is $47.83 with a high price target of $63.00 and a low price target of $33.00. Learn more on PLRX's analyst rating history.

Do Wall Street analysts like Pliant Therapeutics more than its competitors?

Analysts like Pliant Therapeutics more than other Medical companies. The consensus rating score for Pliant Therapeutics is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how PLRX compares to other companies.

Does Pliant Therapeutics's stock price have much upside?

According to analysts, Pliant Therapeutics's stock has a predicted upside of 84.03% based on their 12-month price targets.

What analysts cover Pliant Therapeutics?

Stock Ratings Reports and Tools

This page (NASDAQ:PLRX) was last updated on 5/18/2023 by MarketBeat.com Staff

My Account -